What are the key terms of Michael Forer’s 2,202 share options at GHRS?

The 2,202 share options are immediately fully vested but not exercisable until August 11, 2028 . They have an exercise price of $0.0250 per share and an expiration date of August 11, 2033 , providing long-dated equity-based compensation.

Does the Form 4 indicate any GHRS share sales by Michael Forer?

The Form 4 reports only acquisitions of derivative securities (share option grants) and no sale transactions . Both reported entries use transaction code A , described as a grant, award, or other acquisition, with no corresponding sales or dispositions disclosed.

GH Research PLC (GHRS) grants 102,202 share options to director Michael Forer

Q: What insider transaction did GHRS director Michael Forer report?

Michael Forer reported two grants of share options over GH Research PLC Ordinary Shares. One grant covers 2,202 options and the other 100,000 options , both with an exercise price of $0.0250 per share and expiring on August 11, 2033.

Q: How do the 100,000 GHRS share options granted to Michael Forer vest?

The 100,000 share options vest and become exercisable as follows: 25% on August 11, 2027 , and the remaining 75% in equal monthly installments over the following three years . All carry a $0.0250 exercise price and expire August 11, 2033.

Q: Are Michael Forer’s GHRS option grants immediate purchases of Ordinary Shares?

No. The filings report share option grants , not immediate share purchases. These options give the right to buy Ordinary Shares later at $0.0250 per share , subject to vesting and exercisability schedules, with an expiration date of August 11, 2033 .

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

GH Research PLC director Michael Forer reported two grants of share options over Ordinary Shares. One grant covers 2,202 options at an exercise price of $0.0250 per share, which are immediately fully vested but not exercisable until August 11, 2028 and expire on August 11, 2033. A second grant covers 100,000 options at the same exercise price, expiring August 11, 2033, with 25% vesting and becoming exercisable on August 11, 2027 and the remaining 75% vesting in equal monthly installments over three years thereafter.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Forer Michael

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Options (Right to Buy) ^F1	2,202	$0.00	$0.00
Grant/Award	Share Options (Right to Buy) ^F2	100,000	$0.00	$0.00

Holdings After Transaction: Share Options (Right to Buy) — 102,202 shares (Direct)

Footnotes (2)

F1. The share options are immediately fully vested, but are not exercisable until August 11, 2028.
F2. The share options vest and become exercisable with respect to 25% on August 11, 2027 and with respect to the remaining 75% in equal monthly installments for three years thereafter.

Key Figures

Options Granted (Tranche 1): 2,202 share options Options Granted (Tranche 2): 100,000 share options Exercise Price: $0.0250 per share +3 more

6 metrics

Options Granted (Tranche 1) 2,202 share options Grant of Share Options (Right to Buy) on 2026-08-11

Options Granted (Tranche 2) 100,000 share options Grant of Share Options (Right to Buy) on 2026-08-11

Exercise Price $0.0250 per share Conversion or exercise price for both option grants

Expiration Date August 11, 2033 Expiration for both share option grants

Exercisability Start (2,202 options) August 11, 2028 Options fully vested immediately but not exercisable until this date

Initial Vesting (100,000 options) 25% on August 11, 2027 First vesting date before remaining 75% vests monthly over three years

Key Terms

Share Options (Right to Buy), vest and become exercisable, Ordinary Shares

3 terms

vest and become exercisable financial

"The share options vest and become exercisable with respect to 25% on August 11, 2027."

Ordinary Shares financial

"Share options relate to underlying Ordinary Shares of GH Research PLC."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What insider transaction did GHRS director Michael Forer report?

Michael Forer reported two grants of share options over GH Research PLC Ordinary Shares. One grant covers 2,202 options and the other 100,000 options, both with an exercise price of $0.0250 per share and expiring on August 11, 2033.

Are Michael Forer’s GHRS option grants immediate purchases of Ordinary Shares?

No. The filings report share option grants, not immediate share purchases. These options give the right to buy Ordinary Shares later at $0.0250 per share, subject to vesting and exercisability schedules, with an expiration date of August 11, 2033.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 04:43 PM Accepted by SEC EDGAR 08/13/2026 - 04:41 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Forer Michael

(Last)

(First)

(Middle)

C/O GH RESEARCH PLC

JOSHUA DAWSON HOUSE, DAWSON STREET

(Street)

DUBLIN

D02 RY95

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
GH Research PLC [ GHRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Options (Right to Buy)	$0.025	08/11/2026		A		2,202		⁽¹⁾	08/11/2033	Ordinary Shares	2,202	$0	2,202	D
Share Options (Right to Buy)	$0.025	08/11/2026		A		100,000		⁽²⁾	08/11/2033	Ordinary Shares	100,000	$0	100,000	D

Explanation of Responses:

1. The share options are immediately fully vested, but are not exercisable until August 11, 2028.

2. The share options vest and become exercisable with respect to 25% on August 11, 2027 and with respect to the remaining 75% in equal monthly installments for three years thereafter.

	/s/ Michael Forer	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR